--- title: "Prenetics’ IM8 Brings Lily Collins On Board as Global Ambassador and Shareholder Amid Raised 2026–2027 Guidance" type: "News" locale: "en" url: "https://longbridge.com/en/news/296510440.md" description: "Prenetics Group (PRE) announced that actress Lily Collins has joined IM8 as its first Global Ambassador and shareholder. Concurrently, the company raised its full-year 2026 revenue guidance to $220–$230 million and initiated 2027 guidance of at least $400 million. Prenetics also reported positive consolidated adjusted free cash flow from July 2026 onward, alongside a 'Buy' analyst rating with a $36 price target." datetime: "2026-08-20T14:57:18.000Z" locales: - [zh-CN](https://longbridge.com/zh-CN/news/296510440.md) - [en](https://longbridge.com/en/news/296510440.md) - [zh-HK](https://longbridge.com/zh-HK/news/296510440.md) generator: "portal-rs" --- # Prenetics’ IM8 Brings Lily Collins On Board as Global Ambassador and Shareholder Amid Raised 2026–2027 Guidance The latest update is out from Prenetics Group ( (PRE) ). Prenetics Global Limited, the parent of premium health and longevity brand IM8, operates in the consumer health sector with a focus on science-backed daily nutrition systems. Co-founded with David Beckham, IM8’s flagship Daily Ultimate Essentials consolidates multiple supplements into one NSF-certified drink, supporting a rapidly expanding global business that now ships over 200,000 servings a day to 46 countries and generates the majority of its revenue outside the U.S. On August 20, 2026, Prenetics’ IM8 announced a multi-year global partnership with actress and producer Lily Collins, who becomes both IM8’s first film-and-television Global Ambassador and a shareholder in the company. The collaboration deepens IM8’s reach into global culture and a largely female audience, complementing its roster of sports and wellness ambassadors, and arrives as Prenetics lifts full-year 2026 revenue guidance to $220–$230 million, initiates 2027 guidance of at least $400 million, and reports positive consolidated adjusted free cash flow from July 2026 onward. The most recent analyst rating on (PRE) stock is a Buy with a $36.00 price target. To see the full list of analyst forecasts on Prenetics Group stock, see the PRE Stock Forecast page. **Spark’s Take on PRE Stock** According to Spark, TipRanks’ AI Analyst, PRE is a Neutral. The score is held back primarily by weak financial performance—persistent losses and continued free cash flow burn—despite improving revenue and gross margins and a low-debt balance sheet. Technicals are moderately supportive with the stock trading above key moving averages, while valuation is constrained by a negative P/E and no dividend yield. The latest earnings call adds upside due to raised guidance and strong subscription-led growth metrics, but elevated marketing-driven losses and reporting/guidance clarity risks temper the outlook. To see Spark’s full report on PRE stock, click here. **More about Prenetics Group** Prenetics Global Limited, listed on Nasdaq under the ticker PRE, is a consumer health company focused on advancing human health and longevity. Its flagship brand IM8, co-founded with David Beckham, offers science-backed premium daily nutrition, led by the Daily Ultimate Essentials system that consolidates multiple supplements into a single NSF Certified for Sport daily drink. IM8 has rapidly scaled to an annualized revenue run-rate of about $251 million, ships more than 200,000 servings a day to 46 countries, and targets a global audience through an equity-aligned ambassador roster from elite sports and wellness media. IM8 positions itself at the top end of the core nutrition market, blending medical, academic and space-science expertise to deliver holistic formulations. The brand emphasizes convenience, clean ingredients and performance validation, aiming to replace traditional pill-heavy supplement regimes with a single, all-in-one powder. Prenetics leverages IM8’s fast growth, international footprint and celebrity partnerships to strengthen its presence in premium health and longevity, while maintaining a focus on cash-flow generation and pipeline expansion, including upcoming hydration and gummies products. **Average Trading Volume:** 216,662 **Technical Sentiment Signal:** Buy **Current Market Cap:** $332.6M For an in-depth examination of PRE stock, go to TipRanks’ Overview page. ### Related Stocks - [PRE.US](https://longbridge.com/en/quote/PRE.US.md) - [PRENW.US](https://longbridge.com/en/quote/PRENW.US.md) ## Related News & Research - [Prenetics restates FY2024, FY2023 results in audited annual report amendment](https://longbridge.com/en/news/298058286.md) - [Prenetics’ IM8 CEO and CFO Purchase $1.0 Million of Shares in the Open Market Following Second Quarter Results | PRE Stock News](https://longbridge.com/en/news/297047341.md) - [Hegseth removes 6 Army officers from promotion list](https://longbridge.com/en/news/297714677.md) - [We should call it 'Economic Growth Day'](https://longbridge.com/en/news/298204720.md) - [Did First RASONQUE (daraxonrasib) Approval and NEJM Data Just Shift Revolution Medicines' (RVMD) Investment Narrative?](https://longbridge.com/en/news/298213245.md) --- > **Disclaimer: This article is for reference only and does not constitute any investment advice.**